Trial
NCT06137183
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Vixarelimab
Why stopped
Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-24